Näiden koulutusten sisältö on Novo Nordiskista riippumattoman sisällöntuottajan tuottamaa. Osa koulutuksista on EACCME-akkreditoituja, joten niitä voidaan lukea hyväksi joidenkin erikoisalojen erikoistumisopinnoissa ja diabeteksen erityispätevyyttä suoritettaessa. Pisteiden kelpoisuus täytyy kuitenkin varmistaa koulutuksesta vastaavalta taholta. Novo Nordisk ei vastaa koulutusten sisällöstä. Osa koulutusten järjestäjistä vaatii luomaan erilliset tunnukset omalle sivustolleen.
This course is developed by Medscape Education Global. Medscape is one of the leading digital platforms for medical education. A comprehensive array of innovative formats, in multiple languages, insures the right educational solution is available to best achieve desired objectives—from text-based articles to state-of-the-art multimedia formats and the most sophisticated simulation environments. Activity formats include Clinical Insights, Expert Perspective, Instructional Series Programming, Next-Generation Symposia, Patient-Case Approaches, including Simulation and Clinical Advances.
In this lively inter-disciplinary dialogue between a leading diabetologist and an internationally renowned cardiologist, Dr Naveed Sattar from Glasgow, UK, and Dr Kausik Ray, London, UK, debate the state-of-the art for best diabetes care with a particular focus on latest results from major cardiovascular outomes trials with GLP-1 receptor agonists and SGLT2 inhibitors and how these have shaped the most recent ESC/EASD and EASD/ADA guidelines for the management of patients with type 2 diabetes, especially those at high cardiovascular risk or established CV disease. They further explore the mode-of-action of these novel glucose-lowering drugs with CV benefits and rules for their safe use in clinical practice, and present some typical case studies from cardiology clinic..
Made for: Diabetologists, Endocrinologists, Cardiologists, Primary Care Physicians
Disease areas: Diabetes
Developed by: Medscape
